← All companies
MANNKIND CORP
MNKD - CIK 0000899460
Market cap$1.11 B
Rank#2559
SEC filings1,648
MANNKIND CORP trades as MNKD and has a market capitalization of $1.11 B, making it the #2559 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $348.97M, up 22.2% from the prior year and net income of $5.86M. This page tracks MANNKIND CORP through 1,648 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$348.97MFY 2025
Net income (latest FY)$5.86MFY 2025
Operating cash flow (latest FY)$18.25MFY 2025
Total assets (latest FY)$792.18MFY 2025
Net margin1.7%latest FY
Financial performance
Over the last 9 fiscal years MANNKIND CORP's revenue grew from $174.76M to $348.97M, a compound annual growth rate of 8.0%. Net profit margin compressed from 71.9% to 1.7% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $1.11 B
- Share price (derived)market cap / shares outstanding
- $3.60
- P/E ratio (trailing FY)
- 190.0
- EPS (diluted)FY 2025
- $0.02
- Shares outstandingas of 2026-04-24
- 0.31B
- Long-term debtas of 2026-03-31
- $318.72M
- Cash & equivalentsas of 2026-03-31
- $52.83M
- Current ratioas of 2026-03-31
- 1.87
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
Recent press releases
- MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval2026-05-29
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval | MannKind Corporation
- MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes2026-05-29
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes | MannKind Corporation
- Mannkind Showcase New Data Ada 2026 Advancing Understanding2026-05-29
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems | MannKind Corporation
- MannKind Reports First Quarter 2026 Financial Results and Provides Business Update2026-05-29
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | MannKind Corporation
- MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 20262026-05-29
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 | MannKind Corporation
Similar companies
The largest companies sharing MANNKIND CORP's SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is MANNKIND CORP's market cap?
MANNKIND CORP (MNKD) has a market capitalization of $1.11 B as of 2026-06-10, ranking #2559 among US-listed companies.
How much revenue does MANNKIND CORP make?
MANNKIND CORP reported revenue of $348.97M for fiscal year 2025, an increase of 22.2% year over year.
Is MANNKIND CORP profitable?
Yes. MANNKIND CORP reported net income of $5.86M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.